We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Pandemic Influenza A/H1N1 Detection Kit Released

By LabMedica International staff writers
Posted on 17 Sep 2009
A kit has been released that enables the sensitive and specific detection of the Influenza A/H1N1, the virus that causes the so-called "swine flu", as well as of all other known Influenza A and B virus strains. More...
It was designed for use by governments and public health institutions as part of the efforts to identify and control outbreaks of pandemic influenza strain A/H1N1.

The new artus Influenza/rotor gene/light cycler real time polymerase chain reaction (RG/LC RT-PCR) kit provides accurate results in approximately 40 minutes. Many current molecular solutions and most antigen-based H1N1 tests either take up to several hours to produce results or, in the case of rapid protein-based tests, have been found to have a low sensitivity in detecting the virus.

Complementing Qiagen's (Hilden, Germany) existing portfolio of products for H1N1 screening and surveillance, the new kit can also detect infections with other known Influenza A and B strains that might emerge during the upcoming flu season. The rapid turn around time of the test will result in faster reporting of results, an important factor in monitoring and controlling outbreaks.

Designed for use with Qiagen's automated sample and assay technologies such as the thermo cycler Rotor-Gene Q, the test is also compatible with certain other platforms used in laboratories worldwide, allowing it to be quickly adopted and run on existing instruments without the need for additional training.

"With Qiagen's new test and our existing solutions to support Tamiflu/Oseltamivir resistance testing, we offer healthcare professionals powerful tools not only to quickly and reliably detect the origin of flu-like symptoms in patients, but also to profile the pathogen and thus to rapidly take the necessary actions to control an outbreak," said Peer Schatz, CEO of Qiagen.

The new kit was introduced at the World Economic Forum "Annual Meeting of the New Champions" that took place in Dalian, China, on September 10-12, 2009.

The government of Saudi Arabia is evaluating the possibility of implementing Qiagen's new artus Influenza/H1 RG/LC RT-PCR kit as a screening solution in time to help contain the spread of the virus during the Mecca pilgrimage (November 25-29, 2009).

Related Links:

Qiagen
World Economic Forum



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.